Amundi
CYTK icon

Amundi’s Cytokinetics CYTK Stock Holding History

Amundi’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Sell
12,089
-4,989
-29% -$358K ﹤0.01% 1355
2026
Q1 		$1.13M Buy
17,078
+10,305
+152% +$655K ﹤0.01% 1248
2025
Q4 		$430K Buy
+6,773
New +$421K ﹤0.01% 1531
2025
Q2 		– Sell
-54
Closed -$2.19K – 1793
2025
Q1 		$2.19K Buy
54
+1
+2% +$46 ﹤0.01% 1955
2024
Q4 		$2.51K Buy
+53
New +$2.75K ﹤0.01% 1977
2024
Q1 		– Sell
-13,168
Closed -$1.34M – 2012
2023
Q4 		$1.34M Buy
13,168
+1,140
+9% +$41.3K ﹤0.01% 1282
2023
Q3 		$411K Sell
12,028
-243
-2% -$8.09K ﹤0.01% 1441
2023
Q2 		$409K Sell
12,271
-701
-5% -$25.9K ﹤0.01% 1429
2023
Q1 		$469K Buy
+12,972
New +$529K ﹤0.01% 1375

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Amundi's CYTK Position: Q2 2026 in Review

Amundi reduced its Cytokinetics (CYTK) stake by 29% in Q2 2026, selling an estimated $358K and leaving 12,089 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #1355.

Amundi first reported a position in CYTK in Q1 2023 and has held it in 9 quarters since. The position peaked at $1.34M in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Amundi held 12,089 shares of Cytokinetics worth $1.03M as of Q2 2026.
  • Amundi sold 4,989 Cytokinetics shares in Q2 2026, an estimated $358K.
  • Cytokinetics made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1355 holding.
  • Amundi first reported a position in Cytokinetics in Q1 2023 and has held it in 9 quarters since.
  • Amundi's Cytokinetics position peaked at $1.34M in Q4 2023.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.